Silodosin and its potential for treating premature ejaculation: A preliminary report

International Journal of Urology

Volumn 19, Issue 3, 2012, Pages 268-272

  Sato, Yoshikazu ^a   Tanda, Hitoshi ^a   Nakajima, Hisao ^a   Nitta, Toshikazu ^a   Akagashi, Keigo ^a   Hanzawa, Tatsuo ^a   Tobe, Musashi ^a   Haga, Kazunori ^a   Uchida, Kosuke ^a   Honma, Ichiya ^a  

^a Sanjukai Hospital   (Japan)

Author keywords

1A adrenoceptor antagonists; Intravaginal ejaculatory latency time; Premature ejaculation; Silodosin; Treatment

Indexed keywords

SILODOSIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; EJACULATION; HUMAN; MALE; ORGASM; PREMATURE EJACULATION; PRIORITY JOURNAL; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; TREATMENT OUTCOME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; EJACULATION; HUMANS; INDOLES; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; SELF REPORT; SEMEN; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TIME FACTORS;

EID: 84857362995     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2011.02941.x     Document Type: Article

References (20)

1. Althof SE, Abdo CH, Dean J etal. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J. Sex. Med. 2010; 7: 2947-69.
2. Rowland D, McMahon CG, Abdo C etal. Disorders of orgasm and ejaculation in men. J. Sex. Med. 2010; 7 (4 Pt 2): 1668-86.
3. Montorsi F. Prevalence of premature ejaculation: a global and regional perspective. J. Sex. Med. 2005; 2 (Suppl 2): 96-102.
4. Waldinger MD, McIntosh J, Schweitzer DH. A five-nation survey to assess the distribution of the intravaginal ejaculatory latency time among the general male population. J. Sex. Med. 2009; 6: 2888-95.
5. Pryor JL, Althof SE, Steidle C etal. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929-37.
6. McMahon CG, Althof SE, Kaufman JM etal. Efficacy and safety of dapoxetine for the treatment of premature ejaculation: integrated analysis of results from five phase 3 trials. J. Sex. Med. 2011; 8: 524-39.
7. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev. Urol. 2007; 9: 181-90.
8. Debruyne FM. Alpha blockers: are all created equal? Urology 2000; 56 (Suppl 1): 20-2.
9. Kawabe K, Yoshida M, Homma Y; Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006; 98: 1019-24.
10. Yoshida M, Kudoh J, Homma Y etal. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin. Interv. Aging 2011; 6: 161-72.
11. Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis. 2011; 14: 143-8.
12. Homma Y, Kawabe K, Takeda M, Yoshida M. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010; 76: 1446-50.
13. Kobayashi K, Masumori N, Hisasue S etal. Inhibition of Seminal emission is the main cause of anejaculation induced by a new highly selective alpha1A-blocker in normal volunteers. J. Sex. Med. 2008; 5: 2185-90.
14. Kobayashi K, Masumori N, Kato R, Hisasue S, Furuya R, Tsukamoto T. Orgasm is preserved regardless of ejaculatory dysfunction with selective alpha1A-blocker administration. Int. J. Impot. Res. 2009; 21: 306-10.
15. th edn text version. American Psychiatric Association, Washington, DC, 2000.
16. Patrick DL, Giuliano F, Ho KF, Gagnon DD, McNulty P, Rothman M. The Premature Ejaculation Profile: validation of self-reported outcome measures for research and practice. BJU Int. 2009; 103: 358-64.
17. Althof SE, Brock GB, Rosen RC etal. Validity of the patient-reported Clinical Global Impression of Change as a measure of treatment response in men with premature ejaculation. J. Sex. Med. 2010; 7: 2243-52.
18. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int. J. Urol. 2006; 13: 1311-16.
19. Nagai A, Hara R, Yokoyama T, Jo Y, Fujii T, Miyaji Y. Ejaculatory dysfunction caused by the new alpha1-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int. J. Urol. 2008; 15: 915-18.
20. Tamam L, Ozpoyraz N. Selective serotonin reuptake inhibitor discontinuation syndrome: a review. Adv. Ther. 2002; 19: 17-26.